Strategic Signals Weekly

Cingulate Inc. received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for CTx-1301 (dexmethylphenidate HCl) for Attention Deficit/Hyperactivity Disorder (ADHD). The CRL focused on Chemistry, Manufacturing and Controls (CMC) information requests, without raising concerns about clinical safety or efficacy. Cingulate expects a prompt resubmission to address the FDA's feedback.

Drug: CTx-1301 (dexmethylphenidate HCl) · Indication: Attention Deficit/Hyperactivity Disorder (ADHD)

Celcuity Inc. announced positive detailed efficacy and safety results from its Phase 3 VIKTORIA-1 clinical trial for gedatolisib in PIK3CA mutant-type, HR+/HER2- metastatic breast cancer. The gedatolisib-triplet significantly improved median progression-free survival and objective response rate compared to alpelisib plus fulvestrant. The company plans to submit these data as a supplemental NDA, while also noting the FDA has granted Priority Review for gedatolisib in PIK3CA wild-type ABC with a PDUFA date of July 17, 2026.

Drug: gedatolisib · Indication: HR+, HER2-, PIK3CA MT, locally advanced or metastatic breast cancer (ABC), following progression on, or after, treatment with a CDK4/6 inhibitor and an aromatase inhibitor

Fulcrum Therapeutics, Inc. has approved a restructuring plan, reducing its workforce by approximately 85% and incurring $4.2 million in charges, following the discontinuation of pociredir for sickle cell disease. Concurrently, Fulcrum has initiated a comprehensive review of strategic alternatives to maximize stockholder value, engaging Leerink Partners LLC as its financial advisor. Potential options include a merger, acquisition, business combination, or sale/licensing of assets.

Fulcrum Therapeutics, Inc. announced the discontinuation of its pociredir program, which was being developed for the treatment of sickle cell disease. Concurrently, the company initiated a comprehensive review of strategic alternatives aimed at maximizing stockholder value.

Climb Bio, Inc. announced initial Phase 1 safety data for CLYM116, an anti-APRIL monoclonal antibody, showing it was generally well tolerated in healthy volunteers with no serious adverse events. Translational modeling suggests potential for less-frequent dosing. Climb Bio plans to advance CLYM116 into further clinical development, while its partner Mabworks expects to initiate dosing in IgAN patients in the Phase 2 portion of its ongoing study in Q3 2026.

Drug: CLYM116 · Indication: IgAN · Partner: Mabworks

Mineralys Therapeutics, Inc. entered into a fourth amendment to its license agreement with Tanabe Pharma Corporation for lorundrostat. This amendment grants Mineralys an exclusive, worldwide, royalty-free, perpetual, and irrevocable license, eliminating future royalty payments and diligence obligations to Tanabe. In exchange, Mineralys will make a one-time cash payment of $200 million and remains obligated for certain commercial milestone payments.

Drug: lorundrostat · Partner: Tanabe Pharma Corporation

Travere Therapeutics, Inc. entered into an exclusive license and collaboration agreement with Everest Medicines (Singapore) Pte. Ltd. for civorebrutinib (EVER001), a BTK inhibitor. Travere gains rights for development and commercialization in all countries outside of China and certain East/Southeast Asian countries for broad therapeutic uses, with an initial focus on renal disease. Travere will pay Everest an upfront fee of $112.5 million, with potential for an additional $1.03 billion in clinical, regulatory, and commercial milestones, plus tiered royalties on net sales.

Drug: civorebrutinib (EVER001) · Indication: any and all prophylactic, diagnostic and therapeutic uses and treatment of diseases and disorders, with an initial focus on renal disease and conditions · Partner: Everest Medicines (Singapore) Pte. Ltd.

UroGen Pharma has entered into a settlement and license agreement with Teva Pharmaceuticals, resolving patent litigation related to UroGen's drug Jelmyto (mitomycin). This agreement grants Teva a non-exclusive license to sell a generic version of Jelmyto in the U.S. starting September 15, 2030, pending FDA approval. The litigation stemmed from Teva's Abbreviated New Drug Application (ANDA) seeking to market a generic Jelmyto before UroGen's patents expire.

Drug: Jelmyto (mitomycin) · Indication: pyelocalyceal solution · Partner: Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.

Plus Therapeutics, Inc. has entered into an Equity Distribution Agreement with Canaccord Genuity LLC to establish an at-the-market (ATM) offering. The company may sell up to $17.35 million of its common stock through this offering. Proceeds from the sale of shares are intended for general corporate purposes and working capital.

Unicycive Therapeutics, Inc. amended its at-the-market (ATM) offering sales agreement with Guggenheim Securities, LLC. The amendment increases the aggregate offering price for common stock from $100 million to $150 million. This provides the company with additional financing capacity through the ATM offering.

Syndax Pharmaceuticals, Inc. has entered into privately negotiated subscription agreements for a private placement of $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031. The company expects to receive net proceeds of approximately $243 million, which will be allocated towards general corporate purposes including research and development, commercialization, and business development expenditures. The notes are convertible into common stock at an initial conversion price of approximately $24.76 per share, representing a 35% premium.

Jade Biosciences, Inc. entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, and UBS Securities LLC for a public offering of 10,000,000 shares of common stock at $15.00 per share. The company expects to receive net proceeds of approximately $140.3 million, or up to $161.5 million if the underwriters' option to purchase additional shares is fully exercised. The offering is anticipated to close on June 5, 2026.

Summit Therapeutics Inc.'s Audit Committee and independent directors approved company affiliates to purchase common stock through its existing at-the-market (ATM) offering with JP Morgan Securities LLC. Additionally, Co-CEOs Robert Duggan and Mahkam Zanganeh, along with COO/CFO Manmeet Soni, have indicated their likely intent to purchase shares under the ATM at market prices, though no binding commitments or specific quantities have been disclosed.